Professor Charlotte Deane is a leading academic in structural bioinformatics, holding the position of Professor at the University of Oxford's Department of Statistics and Executive Chair of the Engineering and Physical Sciences Research Council (EPSRC). She leads the Oxford Protein Informatics Group (OPIG), focusing on protein structure prediction, immunoinformatics, and AI-driven drug discovery. Her research integrates computational methods with biological insights, developing tools widely used in academia and industry. Prior roles include Head of the Department of Statistics, Deputy Head of the Mathematical, Physical and Life Sciences (MPLS) Division at Oxford, and Chief Scientist of Biologics AI at Exscientia. During the COVID-19 pandemic, she served on SAGE and as UKRI's COVID-19 Response Director. In 2022, she was awarded an MBE for her contributions to pandemic research. Her research group's work spans antibody design, T-cell receptor analysis, and small molecule discovery, with a focus on open-source software development. Current projects include advancing AI methods for protein structure prediction and therapeutic antibody engineering. Recent publications highlight innovations in computational drug design, antibody developability, and machine learning applications in structural biology.
Geoffrey Tranmer is a Tenured Associate Professor in the College of Pharmacy at the University of Manitoba. His research integrates medicinal chemistry, drug discovery, and synthetic organic methodologies, with a focus on flow chemistry and targeted cancer therapies. NSERC Post-Doctoral Fellow, University of Cambridge Post-Doctoral Fellow, Princeton University PhD in Organic Chemistry, University of Guelph BSc (Hons) in Chemistry, Brock University His research explores: Development of flow chemistry techniques to enhance synthetic organic methods Lead generation and optimization in drug discovery Bioconjugation strategies for chemical biology applications Targeted cancer therapies leveraging hypoxia-activated prodrugs Recent publications highlight his work in neurodegenerative disease drug design, biomarker discovery, and sustainable synthesis technologies. Scientific Awards CIHR Project Grant (2024-2029) NSERC Discovery Grant (2023-2028) CIHR Bridge Grant (2022) NSERC Alliance Grant (2020) NSERC Engage Grant (2017) Research Manitoba New Investigator Operating Grant (2017) Dr. Tranmer's industrial experience at Merck Frosst and academic leadership at Manitoba position him uniquely to bridge chemistry-biology-industry collaborations. His lab actively trains graduate students in cutting-edge synthesis platforms.
Nicolas Thomä is a Full Professor and head of the Thomä Lab at the École Polytechnique Fédérale de Lausanne (EPFL), where he holds the Paternot Chair in Cancer Research. He is affiliated with the School of Life Sciences (SV) and the Institute of Chemical and Biological Technology (ISREC), leading the UPTHOMAE research unit. His work bridges structural biology, chemical biology, and cancer research, with a focus on transcriptional regulation and targeted protein degradation. His research interests center on chromatin biology and the molecular mechanisms by which transcription factors access gene promoters within chromatin. He investigates how multi-protein complexes regulate gene expression, particularly focusing on the role of E3 ubiquitin ligases and molecular glues in targeted protein degradation. His lab combines structural techniques (including cryo-EM), biochemical assays, and functional genomics to unravel how small molecules can rewire protein interactions and induce degradation of disease-relevant proteins, especially transcription factors involved in cancer. The recent publications of his lab demonstrate a strong trajectory in understanding the structural basis of transcription factor binding to nucleosomes (e.g., OCT4-SOX2, MYC-MAX, CLOCK-BMAL1) and the mechanism of action of molecular glues like thalidomide. These studies highlight a shift toward therapeutic innovation through chemical biology, aiming to develop novel strategies for targeting 'undruggable' proteins in human diseases. Scientific Awards No specific awards listed in the provided text. Advising and Grants Thomä actively supervises a team of PhD students and postdoctoral researchers, including David Domjan, Laurin Tim Kanis, Alessandro Minafra, and Pierre Alexander Miranda Herrera. His lab is supported by institutional funding from EPFL and likely external grants related to cancer research, structural biology, and chemical biology, though specific grants are not mentioned. The lab’s interdisciplinary approach suggests collaboration with pharmaceutical and biotech partners. Labs and Teams The Thomä Lab, based at EPFL’s SV building, includes a multidisciplinary team of scientists, technical specialists, and administrative support. Key members include Fiona Bello (Technical Specialist), Regina Baur, Alexandra Bendel, Manuel Carminati, and others. The lab is structured around two main research pillars: Transcription Factors in Chromatin Biology and Ubiquitin Biology and Molecular Glues, reflecting its dual focus on fundamental mechanisms and therapeutic applications.
Vinayak Agarwal is an Assistant Professor at the Georgia Institute of Technology with joint appointments in the School of Chemistry and Biochemistry and School of Biological Sciences within the College of Sciences. His research investigates natural products—small organic molecules produced by living organisms that form the basis of most clinical antibiotics and drugs, while also addressing environmental toxins and pollutants. Dr. Agarwal's work integrates (meta)genomics, biochemistry, structural and mechanistic enzymology, mass spectrometry, and analytical chemistry to answer fundamental questions about natural product biosynthesis. His lab specializes in marine systems, particularly marine sponges and associated microbiomes, with a focus on enzyme discovery, pathway elucidation, and biosynthetic engineering. Key research themes include halogenation enzymes, polyketide synthases, and peptide natural products, driven by the dual goals of drug discovery and environmental protection. Analysis of recent publications reveals a strong emphasis on marine natural product discovery, enzyme characterization, and biosynthetic pathway engineering. His team frequently combines genomic mining with chemical and biochemical validation, with growing attention to environmental implications of natural product chemistry and applications in antibiotic development. Dr. Agarwal has received significant recognition for his research and teaching: ASP Matt Suffness Young Investigator Award (2024) Camille Dreyfus Teacher Scholar award (2023) NSF CAREER award (2023) Cottrell Scholar Award (2021) Blanchard Assistant Professorship (2020) Harold Nation young faculty award (2019) He has mentored multiple PhD students to completion (Ipsita, Dongqi, Luna) and currently advises Vidya and Grace. His lab secures major funding from the NSF (CAREER), NIH (NIGMS MIRA), and Research Corporation for Science Advancement (Cottrell Scholar), alongside the Camille Dreyfus award and Petit Institute seed grants for collaborative marine research. The Agarwal Lab operates from the Petit Biotechnology Building at Georgia Tech and maintains a dynamic team structure with postdocs (Weimao Zhong, Nirmal Saha), graduate students (Sophia, Vidya, Beeta, Grace), and undergraduates. The lab emphasizes interdisciplinary collaboration, particularly with marine biology groups at Georgia Tech and external institutions for sample collection and structural analysis.
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Tobias Sjöblom serves as Professor and Head of Department at Uppsala University's Department of Immunology, Genetics and Pathology, where he leads the Cancer Precision Medicine research program. His work bridges clinical oncology and molecular biology, with particular focus on translating genomic findings into clinical applications for cancer patients. His research interests center on cancer genomics, precision medicine, and molecular diagnostics, with extensive work on colorectal cancer biology and treatment. Sjöblom's laboratory investigates how genetic variations influence cancer development, progression, and response to therapy, particularly focusing on pharmacogenomic biomarkers that can guide personalized treatment decisions. His work spans from basic molecular mechanisms to clinical applications, with strong emphasis on translating research findings into clinical practice. Analyzing his recent publication record reveals a clear trajectory toward precision oncology applications, with increasing focus on liquid biopsy technologies, AI-assisted diagnostics, and biomarker-driven treatment strategies. His research demonstrates a consistent pattern of investigating how specific genetic alterations (particularly in NAT2, CYP2D6, and other metabolic enzymes) can be leveraged for targeted cancer therapies. The interdisciplinary nature of his work is evident in collaborations spanning molecular biology, clinical oncology, bioinformatics, and medical imaging. Sjöblom has established significant research infrastructure through initiatives like the U-CAN biobank, creating valuable resources for cancer research across Sweden. His leadership extends to developing novel methodologies for cancer genomics and diagnostics, including advanced techniques for mutation detection and tissue analysis. His laboratory maintains strong clinical connections, working closely with oncologists and surgeons to ensure research questions address real clinical challenges. This translational approach has resulted in numerous publications in high-impact journals including Nature, Science, and Cell Death and Disease, demonstrating the significance and quality of his contributions to cancer research.
Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.
Mikkel N. Schmidt is an Associate Professor in the Department of Applied Mathematics and Computer Science at the Technical University of Denmark (DTU). His research focuses on statistical modeling, Bayesian methods, and their applications in science and industry. He has held visiting roles at Columbia University (2007) and Cambridge University (2008-2009). His work integrates probabilistic modeling with computational inference to address complex problems in diverse fields such as molecular discovery, optical communication, and brain connectivity analysis. Education highlights include visiting scholar and postdoctoral experiences at top-tier institutions. Research interests span statistical methodology development, machine learning applications, and interdisciplinary problem-solving. Current projects involve Bayesian neural networks for molecular discovery and federated learning optimization. Advising efforts include supervising multiple PhD students in areas like molecular discovery and denoising diffusion models. Notable collaborations involve work on materials science, quantum communication, and medical signal processing. His contributions bridge theoretical advancements with practical industrial applications, emphasizing interdisciplinary innovation.
John F Valliant is a Professor in the Department of Chemistry and Chemical Biology at McMaster University. His research focuses on radiopharmaceutical chemistry, molecular imaging, and targeted therapies, particularly in cancer diagnostics and therapeutics. He co-founded Fusion Pharmaceuticals, a company acquired by AstraZeneca for $2.4 billion (US), which specializes in targeted alpha therapy for cancer treatment. His work includes developing radiolabeled imaging agents for prostate cancer (e.g., [18F]DCFPyL), targeted alpha therapies (e.g., FPI-1434), and bioorthogonal chemistry strategies for pretargeted imaging. Valliant has contributed to advancements in photoacoustic imaging, SPECT/PET modalities, and theranostic agents for conditions like bacterial infections and bone diseases. Key projects include the Phase II clinical trial using 18F-DCFPyL PET-MRI for oligometastatic prostate cancer and studies on individualized dosimetry in Lu-177 therapies. He has pioneered platforms for radiolabeled antibody-recruiting molecules and fluorous-phase chemistry for high-specific-activity probes. Valliant’s research bridges disciplines, integrating chemistry, biology, and clinical applications to address unmet medical needs in oncology and diagnostic imaging.
A.T. Charlie Johnson serves as the Rebecca W. Bushnell Professor of Physics and Astronomy at the University of Pennsylvania's School of Arts & Sciences, where he has been a standing faculty member since 1994. His research program focuses on nanoscale systems and has established him as a leading figure in condensed matter physics, earning recognition from major scientific societies. His educational foundation includes: Ph.D. in Physics from Harvard University (1990) B.S. in Physics from Stanford University (1984) Professor Johnson's research centers on the development and application of atomic-layer nanomaterials, particularly graphene and transition metal dichalcogenides , for fundamental studies of transport phenomena and practical biosensor applications. His group employs advanced nanofabrication techniques at Penn's Singh Center for Nanotechnology to create devices that leverage biological molecules for chemical recognition in disease diagnosis, security screening, and environmental monitoring. This work bridges condensed matter physics with biomedical engineering , yielding innovative solutions for real-world detection challenges. Analysis of his 2023-2025 publications reveals three dominant research thrusts: (1) scalable graphene-based biosensor development for medical diagnostics, (2) exploration of quantum phenomena like Klein tunneling in novel nanoelectromechanical systems, and (3) interdisciplinary applications spanning oncology, planetary science, and fetal medicine. His work consistently emphasizes materials synthesis , device integration , and practical translation of nanoscale phenomena. His scientific contributions have been recognized with prestigious honors: Defense Science Study Group Fellow (2018-2019) Fellow of the American Association for the Advancement of Science (2017) Fellow of the American Physical Society (2011) Lindback Foundation Award for Distinguished Teaching (2003) David and Lucille Packard Foundation Fellowship (1994-1999) As an educator, Professor Johnson has mentored numerous graduate students and postdoctoral researchers, with notable alumni like Michael Biercuk (founder of Q-CTRL). His research has been supported through significant leadership roles including Director of the Nano/Bio Interface Center (2014-2017) and Packard Fellowship funding, enabling sustained innovation in nanotechnology. His group actively collaborates across disciplines to advance both fundamental understanding and practical applications of nanomaterials. Based at the Singh Center for Nanotechnology, Johnson leads a dynamic research team utilizing state-of-the-art facilities for nanofabrication and characterization. His laboratory maintains strong campus collaborations through secondary appointments in Electrical and Systems Engineering and Materials Science and Engineering, fostering an interdisciplinary environment for developing next-generation nanoscale devices.
Eric W. Schmidt is a Distinguished Professor of Medicinal Chemistry at the University of Utah, with adjunct appointments in Biological Sciences and Chemistry. His research focuses on natural products chemistry, biosynthesis, synthetic biology, and pharmaceutical applications of marine animal microbiomes. University of California, San Diego (BS, PhD) Research areas include: Biosynthesis in animals and their microbiomes Synthetic biology approaches to chemical engineering Drug design from marine natural products Metagenomic analysis of symbiotic relationships Neuroactive compound discovery Antibiotic development against resistant pathogens His lab has pioneered methods for: Biosynthetic gene cluster identification Heterologous expression in E. coli Enzymatic modification of peptides Chemical analysis of marine invertebrates Recent publications highlight discoveries in: Marine animal chemical defense mechanisms Evolution of biosynthetic pathways Antibiotic resistance profiling Ionic channel-targeting compounds Peptide macrocyclization techniques Lipid-polyketide biosynthesis continuum Email: ews1@utah.edu Honors include: Distinguished Professor recognition
Francesca Grisoni serves as an Assistant Professor in the Department of Biomedical Engineering at Eindhoven University of Technology (TU/e), where she currently leads the Molecular Machine Learning team. She additionally holds appointments as an ICMS Core member and Associate Professor at EAISI (Eindhoven Artificial Intelligence Systems Institute), reflecting her cross-disciplinary role at the intersection of computational science and biomedical applications. Academic Background : Grisoni completed her Environmental Sciences degree and earned a Ph.D. in 2016 from the University of Milano-Bicocca, where her dissertation focused on interpretable machine learning for molecular property prediction. During doctoral studies, she conducted research at ETH Zurich's Department of Chemistry and Applied Biosciences and the U.S. EPA's National Center for Computational Toxicology. Ph.D., University of Milano-Bicocca, 2016 (Dissertation: Interpretable machine learning for molecular property prediction) Environmental Sciences, University of Milano-Bicocca Her research integrates artificial intelligence, chemistry, and biology to develop computational methods for drug discovery, emphasizing wet-lab experimental validation alongside algorithmic innovation. Key focus areas include overcoming activity cliffs in molecular machine learning, generative modeling for scaffold hopping, and AI-augmented decision-making in therapeutic development, with the ultimate goal of achieving 'better decisions faster' in drug discovery pipelines. Analysis of her recent 2025 publications reveals a concentrated trend toward chemical language models and generative deep learning frameworks, specifically addressing low-data drug discovery challenges through active learning and neural network architectures. These works bridge computer science with pharmacology, targeting bioactivity prediction, molecular representation, and enzyme design while maintaining strong ties to experimental validation. Scientific Awards : Lush Young Researcher Prize Early Career Award 2022 from the Dutch Royal Netherlands Academy of Arts and Sciences (KNAW) ERC Starting Grant (2022) Grants and Supervision : Dr. Grisoni secured the prestigious ERC Starting Grant in 2022 to advance her molecular machine learning research. Institutional records indicate she has supervised 7 students (as shown in TU/e's 'Supervised Work (7)' repository section), though specific names aren't provided in the source material. Her group maintains active industry collaborations, including past engagement with Bracco Pharmaceuticals. Laboratory and Team : The Molecular Machine Learning team operates under the ICMS and EAISI frameworks, merging computational AI development with experimental wet-lab validation. This collaborative unit focuses on fragment-based molecular design, chirality representation (evidenced by fragSMILES work), and high-throughput nanoparticle identification using machine learning, as highlighted in recent press coverage and datasets.
Franklin Goldsmith serves as Associate Professor of Engineering within Brown University's School of Engineering, where his research bridges fundamental chemical kinetics with practical combustion applications. His work directly impacts energy conversion technologies and emission reduction strategies through rigorous investigation of reaction mechanisms. His academic foundation includes: PhD in Chemical Engineering from Massachusetts Institute of Technology (2010) BS in Chemical Engineering from North Carolina State University (2003) BA in Chemistry from University of North Carolina at Chapel Hill (1998) Goldsmith's research program centers on radical reaction kinetics and low-temperature oxidation phenomena , employing both computational master equation modeling and experimental techniques like shock tube spectroscopy and synchrotron photoionization. His investigations into non-Boltzmann energy distributions and pressure-dependent rate coefficients have established new frameworks for understanding ignition chemistry. The Thermochemistry for Combustion Database project exemplifies his commitment to foundational data resources for the field. Analysis of his publication record reveals three dominant research thrusts: (1) detailed kinetic modeling of hydrocarbon oxidation, particularly propane systems; (2) development of computational methodologies for pressure-dependent rate estimation; and (3) fundamental studies of radical-molecule interactions. His work consistently integrates high-precision experimental validation with theoretical frameworks, as evidenced by collaborations with national laboratories. Goldsmith teaches Brown's core chemical engineering curriculum including ENGN 1120 (Reaction Kinetics and Reactor Design) and ENGN 1130 (Chemical Engineering Thermodynamics), alongside specialized graduate courses in heterogeneous catalysis (ENGN 2751) and chemically reacting flow (ENGN 2910Q). His educational approach emphasizes the connection between molecular-scale kinetics and reactor design principles. His research group maintains active collaborations with Argonne National Laboratory (Klippenstein), MIT (Green), and Sandia National Laboratories (Taatjes), focusing on multiscale informatics for complex reaction systems. Current projects investigate biomass-derived fuel combustion and catalytic partial oxidation mechanisms using spatially resolved experimental techniques.
Manu Sharma is an Associate Professor of Neuroscience at the Brain and Mind Research Institute , Weill Cornell Medical College (2024–present). His research focuses on the molecular mechanisms underlying neurodegenerative diseases, particularly tauopathies and synucleinopathies (e.g., Alzheimer’s and Parkinson’s diseases), synaptic transmission, and protein aggregation. Education: Ph.D., University of Toronto (2005) B.Sc., University of Toronto (1998) Research Interests: Dr. Sharma investigates how physiological and pathological modifications of tau and α-synuclein proteins contribute to neurodegeneration. His work explores synaptic vesicle dynamics, chaperone-mediated protein stabilization, and the role of lysosomal pathways in disease progression. Grants: He has secured major funding as Principal Investigator and Co-Investigator from the National Institute on Aging and National Institute of Neurological Disorders & Stroke (2024–2029) for studies on tau proteostasis, synucleinopathies, and small molecule inhibitors targeting neurodegenerative pathways. Labs & Teams: Affiliated with the Brain and Mind Research Institute, Dr. Sharma collaborates on multidisciplinary projects involving synaptic biology, protein quality control, and neurodegeneration models.
Xiaodong Wang is a Professor at the Center for Integrative Chemical Biology and Drug Discovery within the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. His research program focuses on developing innovative drug leads and candidates targeting novel protein kinases and other molecular targets identified by UNC faculty and external investigators. Dr. Wang's research interests center on structure- and ligand-based drug design approaches for developing therapeutic compounds, particularly kinase inhibitors targeting the TAM family (TYRO3, AXL, MERTK). His laboratory has successfully applied these methodologies to deliver compounds to clinical trials, including MerTK inhibitors and IDH1 inhibitors developed in collaboration with NCATS. Current research continues to focus on structure-based drug design for novel targets, with particular emphasis on cancer therapeutics and molecular imaging agents. Analysis of Dr. Wang's recent publications (2023-2025) reveals a strong focus on developing selective kinase inhibitors, particularly targeting the TAM receptor family (TYRO3, AXL, MERTK) for various cancer types including leukemia, Ewing sarcoma, and melanoma. His work spans multiple disciplines including medicinal chemistry, cancer biology, immunology, and molecular imaging, with recent publications appearing in high-impact journals such as Journal of Medicinal Chemistry, Nature Communications, and Leukemia. Dr. Wang maintains active collaborations across UNC-Chapel Hill and with external institutions, working with researchers in pharmacology, oncology, immunology, and structural biology. His laboratory develops both small molecule inhibitors and imaging agents, with several compounds progressing toward clinical applications. Contact information: xiaodonw@email.unc.edu | Wang Lab website
